SICUR 2026 Brokerage Event - Cluster 3

24–26 Feb 2026 | Madrid, Spain

ProductUpdated on 19 January 2026

Rapid Hemostasis Gel Barrier for Emergency and Disaster Response

CEO at Genexica Biotech

Menidi Aetolias-Akarnanias, Greece

About

We offer an innovative bioactive hemostasis gel barrier designed to rapidly stop bleeding by forming a strong, adhesive hydrogel upon contact with blood or moisture.

The solution is particularly effective in irregular, deep or high-flow wounds, where conventional dressings and gauzes are insufficient. It is intended for emergency response, civil protection, disaster scenarios and field conditions, prioritising ease of use, biocompatibility and rapid action without pharmacological vasoconstrictors.

The product is currently at R&D / validation stage, and we are seeking partners for Horizon Europe Cluster 3 activities, including laboratory validation, field testing with first responders, integration into emergency kits and further development toward deployment in disaster-resilient society applications.

Looking for

  • Commercial partners
  • Technological partners
  • Investment opportunities
  • Other

Applies to

  • Chemical, biological and radiological threats
  • Weather, climatic and geological disasters
  • Crisis response and recovery
  • Security against emergencies
  • Ships, submarines, police and rescue vessels, other ships

Organisation

Genexica Biotech

Company

Menidi Aetolias-Akarnanias, Greece

Similar opportunities